“Every experience makes you the person you are. Take those experiences, and you apply them to the situation in front of you.”
In this episode, I talked with Victor Paulus, Senior Vice President and Head of Regulatory Affairs at ARTBIO, where he shares his journey in the life sciences industry, discussing his career journey, challenges faced in regulatory affairs, and the unique culture at ARTBIO. He emphasizes the importance of collaboration, mentorship, and understanding the regulatory landscape to achieve success in drug development. Victor also provides valuable insights into industry observations and offers career advice for those starting in the field.
Here's what you're in:
- What made Victor get into life science and what attracted him to regulatory affairs?
- The challenges faced and approval of Lutathera.
- Why regulatory professionals should be involved early in the development process?
Timestamps:
01:40 Victor's Early Career Journey
06:04 Career Highlights: The Approval of Lutathera
10:25 Challenges in Regulatory Affairs: The CMC Vaccine Program
18:58 The Culture and Vision at ARTBIO
25:07 Industry Observations and Common Mistakes
30:56 Career Advice for New Professionals
About Victor
- Victor Paulus is the Senior Vice President and Head of Regulatory Affairs of ARTBIO, a clinical-stage radiopharmaceutical biotechnology.
- Prior to ARTBIO, he served as Senior Vice President of Regulatory Affairs for two years at Fusion Pharmaceuticals and also worked at AAA during the Lutathera approval.
- He has also worked on approvals including FluZone, Ze-mere-ra ,Pedia-rix, Anthim, Annovera and Lutathera.
- Outside of his professional life, he has been passionate about environmental pursuits and enjoys activities such as birding, hiking, and spending time in the woods.
Connect with Victor
LinkedIn: https://www.linkedin.com/in/victor-paulus-25994a3/
About ARTBIO
- ARTBIO focuses on creating a new class of alpha radioligand therapies (ARTs) using lead-212 (Pb212) as the optimal alpha isotope.
- ARTBIO was founded by the inventors of Xofigo (acquired by Bayer) Roy Larsen and Øyvind Bruland. The ART of ARTBIO is alpha radioligand therapies.
- Leaders of ARTBIO believe that lead (Pb212) is an ideal medical isotope having a short half-life that matches the properties of the small molecule carriers used by ARTBIO, delivering most of its energy into the tumor quickly.
Company Website: https://ARTBIO.com/
Pipeline: https://ARTBIO.com/#pipeline
About me
My name is Charles Spence and I lead Discera. After many years working in the life-science recruitment world, I decided to work for myself. Before doing recruitment I graduated with a biomedical degree, have worked in hospitals (including translation work in Seoul, South Korea), and also spent a year working in diabetes research in Stockholm. After doing research and travel, a career in business and science felt the most appropriate.
In 2023, I decided to launch my firm - Discera Search. A firm committed to solving the biggest talent needs of early clinical stage SME biotechs on the East Coast and DACH.
Connect with me:
LinkedIn: https://www.linkedin.com/in/charles-spence-clinical/
Website: https://www.discera-search.com/
